Develops and commercializes dermatology products for the treatment of acne and other skin conditions.
VYNE Therapeutics Inc., a pharmaceutical company headquartered in Bridgewater, New Jersey, specializes in advancing therapeutics for immuno-inflammatory conditions. At the forefront of its development efforts is FCD105, a topical combination foam that has successfully completed Phase III clinical trials for treating moderate-to-severe acne vulgaris. Additionally, the company is progressing FMX114, a formulation combining tofacitinib, currently undergoing Phase IIa trials aimed at addressing mild-to-moderate atopic dermatitis.
Beyond dermatological treatments, VYNE Therapeutics Inc. is actively exploring VYN201, a promising bromodomain and extra-terminal (BET) inhibitor designed for various immuno-inflammatory diseases, with a particular focus on dermatological applications. Furthermore, the company is advancing VYN202, a series of BET inhibitor compounds selectively targeting bromodomain 2, further expanding its therapeutic portfolio. These innovative developments underscore VYNE's commitment to pioneering treatments that target the underlying causes of complex inflammatory conditions.
Originally established in 2003 as Menlo Therapeutics Inc., the company underwent a significant transformation and rebranding in September 2020 to become VYNE Therapeutics Inc. This strategic evolution reflects its dedication to advancing cutting-edge therapies and expanding its impact in the pharmaceutical landscape. With a robust pipeline and a focus on innovative solutions, VYNE Therapeutics Inc. continues to push the boundaries of medical research and development to improve patient outcomes worldwide.